Journal
GENES
Volume 11, Issue 6, Pages -Publisher
MDPI
DOI: 10.3390/genes11060619
Keywords
cystic fibrosis; CFTR; CFTR-related disorders; molecular diagnosis; CFTR variants; Next Generation Sequencing (NGS); disease liability; interpretation; penetrance; genotype-guided therapy
Categories
Funding
- Vaincre La Mucoviscidose
Ask authors/readers for more resources
Identification of the cystic fibrosis transmembrane conductance regulator(CFTR)gene and its numerous variants opened the way to fantastic breakthroughs in diagnosis, research and treatment of cystic fibrosis (CF). The current and future challenges of molecular diagnosis of CF and CFTR-related disorders and of genetic counseling are here reviewed. Technological advances have enabled to make a diagnosis of CF with a sensitivity of 99% by using next generation sequencing in a single step. The detection of heretofore unidentified variants and ethnic-specific variants remains challenging, especially for newborn screening (NBS), CF carrier testing and genotype-guided therapy. Among the criteria for assessing the impact of variants, population genetics data are insufficiently taken into account and the penetrance of CF associated withCFTRvariants remains poorly known. The huge diversity of diagnostic and genetic counseling indications forCFTRstudies makes assessment of variant disease-liability critical. This is especially discussed in the perspective of wide genome analyses for NBS and CF carrier screening in the general population, as future challenges.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available